1.405
0.36%
+0.005
Pre-market:
1.41
0.005
+0.36%
Spero Therapeutics Inc stock is currently priced at $1.405, with a 24-hour trading volume of 295.57K.
It has seen a +0.36% increased in the last 24 hours and a -19.71% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.45 pivot point. If it approaches the $1.35 support level, significant changes may occur.
Spero Therapeutics Inc Stock (SPRO) Financials Data
Spero Therapeutics Inc (SPRO) Revenue 2024
SPRO reported a revenue (TTM) of $76.19 million for the quarter ending September 30, 2023, a +331.28% rise year-over-year.
Spero Therapeutics Inc (SPRO) Net Income 2024
SPRO net income (TTM) was -$1.61 million for the quarter ending September 30, 2023, a +98.42% increase year-over-year.
Spero Therapeutics Inc (SPRO) Cash Flow 2024
SPRO recorded a free cash flow (TTM) of $28.98 million for the quarter ending September 30, 2023, a +136.42% increase year-over-year.
Spero Therapeutics Inc (SPRO) Earnings per Share 2024
SPRO earnings per share (TTM) was $0.01 for the quarter ending September 30, 2023, a +100.32% growth year-over-year.
Spero Therapeutics Inc Stock (SPRO) Latest News
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
GlobeNewswire Inc.
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
GlobeNewswire Inc.
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
GlobeNewswire Inc.
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):